Dengue Vaccines Market Poised to Achieve Significant Growth in the Years to Come
Dengue is a
mosquito-borne flavivirus debilitating disease with high prevalence
in most tropical and sub-tropical regions. Dengue is a painful
disease that is also known as ‘break bone’ fever due to the
excruciating bone and joint pain associated with it. No therapeutics
have been discovered for treatment of the disease caused by four
closely related dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4).
Therefore, focus has been mainly on prevention by controlling the
vectors being borne. Severe dengue was discovered in the 1950s during
dengue epidemics in Philippines and Thailand. The disease has since
spread to Asian and Latin America countries and is one of the leading
causes of hospitalization and deaths among children and adults in
these regions.
Request for a
Sample Copy of This Research Report:
Prevalent
Scenario in the Global Dengue Vaccines Market
Member states in
three of the WHO regions regularly report the annual number of dengue
cases. These statistic suggest that the number of dengue cases
increased from 2.2 million in 2010 to 3.2 million in 2015. The actual
number remains underreported. One recent estimate by Bhatt et al.,
(also quoted by the WHO) mentions that there are around 390 million
dengue cases worldwide each year, with number of cases reported
increasing each year. In 2015, 2.35 million cases of dengue were
reported in the Americas alone, of which 10,200 cases were diagnosed
as severe dengue that led to 1,181 deaths. Dengue is a pertinent
health issue affecting people across South America, Europe, and Asia.
A large number of
dengue outbreaks were reported worldwide in 2015, with over 169,000
cases in the Philippines and over 111,000 suspected cases of dengue
in Malaysia. This was a staggering 59.5% and 16% increase
respectively in the number of cases compared to that in 2014. The
global dengue vaccines market therefore, offers lucrative growth
opportunities for vaccine manufacturers.
Dengvaxia – the
only approved product in the global dengue vaccines market
Sanofi Pasteur’s
Dengvaxia, is the culmination of over two decades of scientific
innovation and collaboration. The vaccine received its first
marketing authorization in 2015, in Mexico. Dengvaxia is the world’s
first licensed vaccine for prevention of dengue. It is a tetravalent
dengue vaccine that prevents the disease from all four dengue viruses
in people aged 9 to 45 years. Sanofi launched the world’s first
public dengue vaccination program in the Philippines (2016), followed
by Brazil. Dengvaxia is approved in 10 endemic countries worldwide,
namely, Singapore, Mexico, the Philippines, Paraguay, Brazil, El
Salvador, Costa Rica, Indonesia, Peru, and Guatemala. The global
dengue vaccines market is thus, expected to expand with growing
market approvals.
India is however
taking a precautionary approach in approving this vaccine due to lack
of studies among the population in the country. A scientist in India
has developed a dengue vaccine that was successfully tested in
monkeys. If successful in human trials, this could be a breakthrough
invention for prevention of dengue among the populace in the country.
Moreover, various philanthropists and global organizations are
investing in developing vaccines for malaria and dengue.
Download the PDF
brochure:
Dengue Vaccines
Market Outlook – Research Pipeline
There are
approximately five vaccine candidates under evaluation in clinical
trials, including other live-attenuated vaccines, as well as subunit,
DNA and purified inactivated vaccine candidates. Also, technological
approaches, such as virus-vectored and VLP-based vaccines, are under
evaluation in preclinical studies. In September 2016, Takeda
announced the beginning of the phase 3 clinical trials of its dengue
vaccine – TAK-003 vaccine. This vaccine is also aimed at prevention
against all four dengue virus strains. Click To Read More On
Dengue
Vaccines Market
Comments
Post a Comment